Previous 10 | Next 10 |
Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...
Assembly Biosciences (ASMB) announces data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733) at EASL Liver Congress 2021.ASMB shares up 3% premarket trading at $4.09. In an oral presentation, William Delaney,...
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced data from its three clinical-stage core inhibitor programs, ...
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation dur...
The chief financial officer of Assembly Biosciences ([[ASMB]] -1.5%) Thomas J. Russo is leaving the company, the company said in a regulatory filing yesterday.Mr. Russo who also served the company as principal financial officer and principal accounting officer has notified the company of...
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that Lisa Johnson-Pratt, M.D., has joined the company’...
Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are updating our model post the 1Q21 print (no major changes, PT still $13). The stock hit a new all-time low last night, closing at $3.9...
Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Assembly released its 1Q21 results after the bell, and we had a chance to catch up with management this evening. The new information is incr...
Assembly Biosciences (ASMB): Q1 GAAP EPS of -$0.69 beats by $0.10.Cash, cash equivalents and marketable securities of $214.9MPress Release For further details see: Assembly Biosciences EPS beats by $0.10
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter end...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-04-07 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with rec...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...